[go: up one dir, main page]

RU2005128124A - Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности - Google Patents

Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности Download PDF

Info

Publication number
RU2005128124A
RU2005128124A RU2005128124/15A RU2005128124A RU2005128124A RU 2005128124 A RU2005128124 A RU 2005128124A RU 2005128124/15 A RU2005128124/15 A RU 2005128124/15A RU 2005128124 A RU2005128124 A RU 2005128124A RU 2005128124 A RU2005128124 A RU 2005128124A
Authority
RU
Russia
Prior art keywords
atii
angiotensin
patient
receptor antagonist
type
Prior art date
Application number
RU2005128124/15A
Other languages
English (en)
Other versions
RU2378018C2 (ru
Inventor
Бернвард ШЕЛКЕНС (DE)
Бернвард Шелкенс
Норберт БЕНДЕР (DE)
Норберт Бендер
Бадрудин РАНГООНВАЛА (DE)
Бадрудин Рангоонвала
Жилль ДАЖЕНЕ (CA)
Жилль Дажене
Хертцель ГЕРШТАЙН (CA)
Хертцель Герштайн
Андерс ЮНГГРЕН (SE)
Андерс Юнггрен
Салим ЮСУФ (CA)
Салим Юсуф
Original Assignee
АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE)
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20416770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2005128124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE), Авентис Фарма Дойчланд Гмбх filed Critical АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE)
Publication of RU2005128124A publication Critical patent/RU2005128124A/ru
Application granted granted Critical
Publication of RU2378018C2 publication Critical patent/RU2378018C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (9)

1. Применение антагониста рецептора ангиотензина (II) (ATII) типа 1 или его фармацевтически приемлемой соли для изготовления лекарственного средства для предотвращения или снижения риска удара у пациента, который имеет, по существу, поддерживаемую функцию сердца, и пациент подвержен высокому риску сердечно-сосудистого приступа ввиду истории предшествующей ишемической болезни, удара или периферической артериальной болезни.
2. Применение антагониста рецептора ангиотензина (II) (ATII) типа 1 или его фармацевтически приемлемой соли для изготовления лекарственного средства для предотвращения или снижения риска возникновения диабета у пациента, подверженного высокому риску сердечно-сосудистого приступа ввиду предыдущей истории ишемической болезни сердца, удара или периферической артериальной болезни.
3. Применение антагониста рецептора ангиотензина (II) (ATII) типа 1 или его фармацевтически приемлемой соли для изготовления лекарственного средства для предотвращения или снижения риска застойной сердечной недостаточности (CHF) у пациента, ранее не имевшего CHF и который имеет по существу поддерживаемую функцию сердца, где пациент подвержен высокому риску сердечно-сосудистого приступа вследствие истории предыдущей ишемической болезни сердца, удара или периферической артериальной болезни.
4. Применение по любому из пп.1-3, отличающееся тем, что пациент имеет нормальное или пониженное кровяное давление.
5. Применение по любому из пп.1-3, отличающееся тем, что пациент страдает диабетом.
6. Применение по любому из пп.1-3, где антагонист рецептора ангиотензина (II) (ATII) типа 1 или его фармацевтически приемлемая соль выбраны из группы, состоящей из кандесартана, кандесартана цилексетила, лозартана, валсартана, ирбесартана, тасосартана, телмисартана и эпросартана.
7. Применение по п.4, где антагонист рецептора ангиотензина (II) (ATII) типа 1 или его фармацевтически приемлемая соль выбраны из группы, состоящей из кандесартана, кандесартана цилексетила, лозартана, валсартана, ирбесартана, тасосартана, телмисартана и эпросартана.
8. Применение по п.5, где антагонист рецептора ангиотензина (II) (ATII) типа 1 или его фармацевтически приемлемая соль выбраны из группы, состоящей из кандесартана, кандесартана цилексетила, лозартана, валсартана, ирбесартана, тасосартана, телмисартана и эпросартана.
9. Применение по любому из пп.1-3,7 и 8, где антагонист рецептора ангиотензина (II) (ATII) типа 1 выбран из группы, состоящей из кандесартана и кандесартана цилексетила.
RU2005128124/15A 1999-08-27 2005-09-08 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности RU2378018C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use
SE9903028-0 1999-08-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2002107673/15A Division RU2272651C2 (ru) 1999-08-27 2000-08-25 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности

Publications (2)

Publication Number Publication Date
RU2005128124A true RU2005128124A (ru) 2007-03-20
RU2378018C2 RU2378018C2 (ru) 2010-01-10

Family

ID=20416770

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2002107673/15A RU2272651C2 (ru) 1999-08-27 2000-08-25 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
RU2005128124/15A RU2378018C2 (ru) 1999-08-27 2005-09-08 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2002107673/15A RU2272651C2 (ru) 1999-08-27 2000-08-25 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности

Country Status (35)

Country Link
US (6) US20060194868A1 (ru)
EP (4) EP1212081B2 (ru)
JP (1) JP4843172B2 (ru)
KR (2) KR20020060167A (ru)
CN (2) CN101537181A (ru)
AT (2) ATE307604T1 (ru)
AU (3) AU7648400A (ru)
BG (2) BG66115B1 (ru)
BR (1) BR0013540A (ru)
CA (1) CA2382387C (ru)
CY (2) CY1112987T1 (ru)
CZ (1) CZ303433B6 (ru)
DE (1) DE60023518T3 (ru)
DK (3) DK1437131T3 (ru)
EE (1) EE05130B1 (ru)
ES (3) ES2250192T5 (ru)
HR (1) HRP20020169A2 (ru)
HU (1) HU229107B1 (ru)
IL (1) IL148126A (ru)
ME (1) ME00181B (ru)
MX (1) MXPA02001633A (ru)
NO (2) NO329245B1 (ru)
NZ (1) NZ571901A (ru)
PL (1) PL353066A1 (ru)
PT (2) PT1925303E (ru)
RS (1) RS52907B (ru)
RU (2) RU2272651C2 (ru)
SE (1) SE9903028D0 (ru)
SI (3) SI1212081T2 (ru)
SK (1) SK288239B6 (ru)
TR (5) TR200200518T2 (ru)
UA (2) UA76702C2 (ru)
WO (1) WO2001015673A2 (ru)
YU (1) YU3602A (ru)
ZA (1) ZA200201471B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2276997C2 (ru) 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
KR20030083010A (ko) 2001-03-26 2003-10-23 고토부키 세이야쿠 가부시키가이샤 이소퀴누클리딘 유도체와 그 제조방법 및 이것을 함유하는 의약조성물
AU2002335843A1 (en) * 2001-10-17 2003-04-28 King Pharmaceuticals Research And Development, Inc Use of ace inhibitors for reducing type 2 diabetes in high risk patients
US6844361B2 (en) 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
RU2367442C2 (ru) 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
EP1687006B1 (en) * 2003-11-18 2007-11-14 Solvay Pharmaceuticals GmbH Pharmaceutical compositions for the treatment of renal dysfunction
EP1977741A3 (en) * 2004-03-17 2009-10-14 Novartis AG Use of renin inhibitors in therapy
ZA200704767B (en) * 2004-11-05 2008-08-27 King Pharmaceuticals Res & Dev Stabilized individually coated ramipril particles, compositions and methods
US20070208041A1 (en) * 2005-10-13 2007-09-06 Stamler Jonathan S Compositions for the treatment and prevention of heart disease and methods of using same
BRPI0716411A2 (pt) * 2006-08-28 2013-09-24 Sanofi Aventis Deutschland mÉtodos para o abaixamento dos nÍveis de glicose
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
ES2692291T3 (es) 2008-05-01 2018-12-03 Complexa Inc. Ácidos grasos vinil sustituidos
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US8338565B2 (en) 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
JP2013500966A (ja) 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
JP5647338B2 (ja) 2010-05-14 2014-12-24 サバンジ・ウニヴェルシテシＳａｂａｎｃｉ Ｕｎｉｖｅｒｓｉｔｅｓｉ 流体力学的キャビテーションを治療に利用するための装置
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2016176338A1 (en) * 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Small molecule ras ligands
ES2971969T3 (es) 2015-07-07 2024-06-10 H Lundbeck As Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
KR20180098222A (ko) 2015-10-02 2018-09-03 컴플렉사, 인코포레이티드 활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행
MA52792A (fr) 2018-05-25 2021-04-14 Imara Inc Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one
CN110833620A (zh) * 2018-08-15 2020-02-25 王镕 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
KR20230137654A (ko) * 2022-03-22 2023-10-05 주식회사 메디포럼 뇌졸중의 예방 및 치료용 조성물

Family Cites Families (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (ru) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3413710A1 (de) 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
EP0241201A3 (en) * 1986-04-07 1990-05-23 Merck & Co. Inc. Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
DE3704661A1 (de) 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0331014A3 (de) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
US5217958A (en) * 1988-03-03 1993-06-08 E. R. Squibb & Sons, Inc. 1,2-hydroxy phosphonates and derivatives thereof
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
CA2003382A1 (en) * 1988-11-21 1990-05-21 Hollis D. Kleinert Method for treating vascular diseases
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018443A1 (en) 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
ATE190051T1 (de) 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
WO1991000281A2 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Fused-ring aryl substituted imidazoles
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE69024556T2 (de) 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
ATE113281T1 (de) 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
BG92674A (bg) 1989-08-11 1993-12-24 David Roberts Метод за получаване на производни на хинолина
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5100897A (en) 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0424317A3 (en) 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
CA2027937A1 (en) 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
IL96019A0 (en) 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (en) 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
GB8927277D0 (en) 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
JPH03223281A (ja) 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5104891A (en) 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
CA2032289A1 (en) 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles
WO1991012002A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
EP0515546A4 (en) 1990-02-13 1993-05-12 Merck & Co. Inc. Triazole angiotensin ii antagonists incorporating a substituted benzyl element
EP0515535A4 (en) 1990-02-13 1996-01-17 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
EP0515357B1 (de) 1990-02-14 1996-01-10 Siemens Aktiengesellschaft Verfahren zur demodulation von secam-codierten farbfernsehsignalen mit zeilenverkoppeltem takt und schaltungsanordnung zur durchführung des verfahrens
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
CA2036618C (en) 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
DE4006693A1 (de) 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5044166A (en) 1990-03-05 1991-09-03 Membrane Technology & Research, Inc. Refrigeration process with purge and recovery of refrigerant
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
GB9005354D0 (en) 1990-03-09 1990-05-02 Glaxo Group Ltd Chemical compounds
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
EP0522038A4 (en) 1990-03-30 1993-05-26 Merck & Co. Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
CA2079343A1 (en) 1990-03-30 1991-10-01 Eric E. Allen Substituted pyrazoles, isoxazoles and isothiazoles
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
AU7759591A (en) 1990-04-13 1991-11-11 Smithkline Beecham Corporation Substituted benzimidazoles
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5098920A (en) 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
CA2041763A1 (en) 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
JPH05506443A (ja) 1990-05-25 1993-09-22 ジー．ディー．サール　アンド　カンパニー 心臓血管障害の治療用ｎ―置換１，２，４―トリアゾロン化合物
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
JPH04235974A (ja) 1990-06-08 1992-08-25 Roussel Uclaf 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
ES2121773T3 (es) 1990-06-08 1998-12-16 Hoechst Marion Roussel Inc Derivados de bencimidazol, su procedimiento de preparacion, productos intermedios, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
WO1991019715A1 (en) 1990-06-15 1991-12-26 G.D. Searle & Co. 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
US5399566A (en) 1990-06-19 1995-03-21 Meiji Seika Kabushiki Kaisha Pyridine derivatives having angiotensin II antagonism
EP0533840B1 (en) 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
NZ238688A (en) 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
IL98319A (en) 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
CA2044806A1 (en) 1990-07-18 1992-01-19 Roland Jaunin Purine derivatives
CA2047029A1 (en) 1990-07-19 1992-01-20 Shieh-Shung T. Chen Microbial transformation process for antihypertensive products
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
RU1836357C (ru) 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
NZ239161A (en) 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
EP0470543A1 (de) 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
US5217985A (en) 1990-08-28 1993-06-08 G. D. Searle & Co. Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
AU8405691A (en) 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
US5140036A (en) 1990-09-19 1992-08-18 G. D. Searle & Co. 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
US5126342A (en) 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
CA2053148A1 (en) 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5430145A (en) 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
WO1992007852A1 (en) 1990-10-25 1992-05-14 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
AU636066B2 (en) 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
DE4036706A1 (de) 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9025123D0 (en) 1990-11-19 1991-01-02 Ici Plc Nitrogen compounds
GB9026006D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Chemical compounds
AU9055391A (en) 1990-11-30 1992-06-25 Smithkline Beecham Corporation Substituted 5-aryl imidazoles
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
WO1992010189A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
US5175180A (en) 1990-12-20 1992-12-29 G. D. Searle & Co. N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders
CA2058198A1 (en) 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
AT395853B (de) 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
ES2104862T3 (es) 1991-02-07 1997-10-16 Roussel Uclaf Derivados biciclicos nitrogenados, su procedimiento de preparacion, sus productos intermedios obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9102804D0 (en) 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
GB9102803D0 (en) 1991-02-11 1991-03-27 Ici Plc Pyridine compounds
IE920175A1 (en) 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
FR2673427B1 (fr) 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
EP0503838A3 (en) 1991-03-08 1992-10-07 Merck & Co. Inc. Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
EP0505098A1 (en) 1991-03-19 1992-09-23 Merck & Co. Inc. Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
US5128327A (en) 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
JPH06505979A (ja) 1991-03-25 1994-07-07 グラクソ、グループ、リミテッド ベンゾフラン誘導体
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5157040A (en) 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5155117A (en) 1991-04-12 1992-10-13 G. D. Searle & Co. 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
TW274551B (ru) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
SK117793A3 (en) 1991-04-29 1994-05-11 Merck & Co Inc Optimized tablet formulation
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
JPH05112533A (ja) 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5506361A (en) * 1991-05-08 1996-04-09 Theupjohn Company Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
US5162340A (en) 1991-05-10 1992-11-10 Merck & Co., Inc. Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
GB9110532D0 (en) 1991-05-15 1991-07-03 Smithkline Beecham Corp Chemical compounds
EP0514192A1 (en) 1991-05-16 1992-11-19 Glaxo Group Limited Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups
GB9110625D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110635D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
AU654349B2 (en) 1991-05-16 1994-11-03 Glaxo Group Limited Benzofuran derivatives
GB9110623D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
WO1992021666A1 (fr) 1991-05-31 1992-12-10 Laboratoires Upsa Derives de thiazole antagonistes de recepteurs a l'angiotensine ii
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
US5175164A (en) 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5210211A (en) 1991-06-21 1993-05-11 Warner-Lambert Company 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
GB9113626D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
WO1993001177A1 (en) 1991-07-03 1993-01-21 Merck & Co., Inc. Substituted triazolinones
FR2678618B1 (fr) 1991-07-05 1993-11-05 Upsa Laboratoires Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1993003033A1 (en) 1991-07-26 1993-02-18 G. D. Searle & Co. CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
WO1993003040A1 (fr) 1991-08-05 1993-02-18 Taisho Pharmaceutical Co., Ltd. Derive de thienopyrimidin-4-one
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5246944A (en) 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
ES2101824T3 (es) 1991-08-15 1997-07-16 Ciba Geigy Ag N-acil-n-heterociclil-onaftalenil-alquil-aminoacidos como antagonistas de angiotensina ii.
DE69223575T2 (de) 1991-09-20 1998-04-16 Lgl Electronics Spa Selbstregulierende Fadenbremse für eine Schussfadenliefervorrichtung
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
ZA927211B (en) 1991-09-27 1993-03-24 Merrell Dow Pharma Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
JPH06107661A (ja) * 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
HU223663B1 (hu) 1992-05-15 2004-11-29 Merrel Dow Pharmaceuticals Inc. Enkefalináz és ACE gátló hatású 9-[(2-acetil-tio-3-fenil)-propanoil-amino]-piridazo[1,2-a][1,2]diazepin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
WO1994002142A1 (en) * 1992-07-17 1994-02-03 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
DE4308504A1 (de) * 1993-03-18 1994-09-22 Knoll Ag Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
EP0671172A4 (en) 1993-06-11 1998-09-02 Eisai Co Ltd AMINO ACID DERIVATIVE.
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2079315B1 (es) * 1994-02-24 1996-10-16 Uriach & Cia Sa J Nuevas imidazopiridinas.
ES2105939B1 (es) * 1994-08-02 1998-07-01 Uriach & Cia Sa J Nuevos pirazoles con actividad antagonista de la angiotensina ii.
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ATE243529T1 (de) * 1995-02-10 2003-07-15 Searle & Co Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
AU2252297A (en) * 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DE69712338T2 (de) * 1996-06-24 2002-11-07 Merck & Co., Inc. Zusammensetzung auf basis von enalapril und losartan
CN1249682A (zh) * 1997-01-10 2000-04-05 麦克公司 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
HU0900792D0 (en) * 1997-10-17 2010-03-01 Ark Therapeutics Ltd Use of renin-angiotensin inhibitors
US6097772A (en) * 1997-11-24 2000-08-01 Ericsson Inc. System and method for detecting speech transmissions in the presence of control signaling
JPH11222439A (ja) * 1998-02-03 1999-08-17 Dainippon Pharmaceut Co Ltd 脳血管攣縮抑制薬
ID25640A (id) * 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
PT1096932E (pt) * 1998-07-10 2007-09-21 Novartis Pharma Ag ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio''
DE19913528A1 (de) * 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
WO2000071751A1 (en) * 1999-05-21 2000-11-30 Myriad Genetics, Inc. Diabetes gene
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
MXPA04004844A (es) * 2001-11-23 2004-07-30 Solvay Pharm Gmbh Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.
ITBO20030050A1 (it) * 2003-02-06 2004-08-07 Ima Spa Macchina per il trattamento di prodotti farmaceutici.

Also Published As

Publication number Publication date
CA2382387A1 (en) 2001-03-08
EP1925303A2 (en) 2008-05-28
TR200202467T2 (tr) 2002-12-23
AU2005203694A1 (en) 2005-09-08
JP2003508426A (ja) 2003-03-04
DE60023518T3 (de) 2014-08-28
PL353066A1 (en) 2003-10-06
RU2272651C2 (ru) 2006-03-27
TR200200518T2 (tr) 2002-06-21
UA88270C2 (ru) 2009-10-12
EP1212081B2 (en) 2014-04-02
TR200202466T2 (tr) 2002-12-23
TR200202464T2 (tr) 2003-01-21
BG66115B1 (bg) 2011-05-31
EE05130B1 (et) 2009-02-16
IL148126A (en) 2014-12-31
EP2277519A3 (en) 2011-09-07
ES2386141T3 (es) 2012-08-10
SE9903028D0 (sv) 1999-08-27
NO20020850L (no) 2002-02-21
KR20020060167A (ko) 2002-07-16
EP1212081A2 (en) 2002-06-12
US20060194868A1 (en) 2006-08-31
BG110479A (en) 2010-01-29
BG106319A (bg) 2002-12-29
CN100408093C (zh) 2008-08-06
SI1925303T1 (sl) 2015-01-30
RU2378018C2 (ru) 2010-01-10
PT1925303E (pt) 2014-12-18
DK1925303T3 (en) 2015-01-05
EP1212081B8 (en) 2005-12-28
DE60023518T2 (de) 2006-07-06
MEP28208A (en) 2010-10-10
ATE307604T1 (de) 2005-11-15
EP1212081B1 (en) 2005-10-26
JP4843172B2 (ja) 2011-12-21
ATE554761T1 (de) 2012-05-15
ZA200201471B (en) 2003-05-28
CA2382387C (en) 2005-06-21
BR0013540A (pt) 2002-04-30
CZ2002644A3 (cs) 2002-05-15
ES2250192T3 (es) 2006-04-16
CZ303433B6 (cs) 2012-09-12
UA76702C2 (ru) 2006-09-15
US20090258919A1 (en) 2009-10-15
EP2277519A2 (en) 2011-01-26
EP1925303A3 (en) 2010-12-08
DK1437131T3 (da) 2012-08-06
WO2001015673A2 (en) 2001-03-08
ES2250192T5 (es) 2014-06-27
ES2525699T3 (es) 2014-12-29
US20080125472A1 (en) 2008-05-29
NO20100569L (no) 2002-02-21
US20110263619A1 (en) 2011-10-27
AU2009200551A1 (en) 2009-03-05
SI1212081T1 (sl) 2006-06-30
DK1212081T4 (da) 2014-07-07
US20130317047A1 (en) 2013-11-28
DK1212081T3 (da) 2006-01-16
RU2002107673A (ru) 2004-01-10
HRP20020169A2 (en) 2005-10-31
US20100267798A1 (en) 2010-10-21
SI1437131T1 (sl) 2012-09-28
KR20080035703A (ko) 2008-04-23
AU2009200551B2 (en) 2010-09-30
HU229107B1 (en) 2013-07-29
SK288239B6 (sk) 2015-02-03
HUP0202461A2 (hu) 2002-12-28
SI1212081T2 (sl) 2014-08-29
NZ571901A (en) 2010-05-28
CN1384756A (zh) 2002-12-11
IL148126A0 (en) 2002-09-12
EE200200085A (et) 2003-04-15
WO2001015673A3 (en) 2002-03-07
YU3602A (sh) 2004-12-31
EP1437131B1 (en) 2012-04-25
CN101537181A (zh) 2009-09-23
MXPA02001633A (es) 2002-08-06
NO329245B1 (no) 2010-09-20
HUP0202461A3 (en) 2003-04-28
EP1437131A1 (en) 2004-07-14
SK2702002A3 (en) 2002-09-10
DE60023518D1 (de) 2005-12-01
TR200202463T2 (tr) 2003-01-21
CY1112987T1 (el) 2016-04-13
PT1437131E (pt) 2012-07-12
RS52907B (sr) 2014-02-28
AU7648400A (en) 2001-03-26
ME00181B (me) 2010-10-10
EP1925303B1 (en) 2014-09-24
NO20020850D0 (no) 2002-02-21
CY1115869T1 (el) 2017-01-25
HK1050327A1 (zh) 2003-06-20

Similar Documents

Publication Publication Date Title
RU2005128124A (ru) Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
JP6993502B2 (ja) Ｓｇｌｔ－２阻害剤とアンジオテンシン受容体拮抗薬を含む医薬組成物
JP2011520918A5 (ru)
RU2005141759A (ru) Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
CN101450211A (zh) 复方降压制剂
CA2532450A1 (en) Chlorthalidone combinations
AU716519B2 (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
CN101715448B (zh) 一种咪唑-5-羧酸衍生物的治疗用途
Lacourcière A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide
RU2004137109A (ru) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
CN104324377B (zh) 一种复方降压制剂及其应用
Silverstein et al. Angiotensin-receptor blockers: benefits beyond lowering blood pressure
Chrysant et al. Effects of atenolol and diltiazem‐SR on exercise and pressure load in hypertensive patients
EP1787647A1 (en) Remedy for glomerular diseae
RU2006119329A (ru) Комбинации ат1-антагонистов, амилорида или триаметерина, и диуретика
Van der Merwe Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients
Blake et al. Renal protection: are all antihypertensive drugs comparable?
RU2222328C2 (ru) Фармацевтические комбинированные препараты
HRP20030124A2 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
CN102552255A (zh) 氨氯地平、阿利可伦和沙坦类复方降压药物
Konradi et al. Arterial hypertension workgroup resolution. The role of sartans in treatment of systemic hypertension in the 21st century
Farsang et al. Optimizing antihypertensive therapy by angiotensin receptor blockers
Sarzani et al. Angiotensin receptor blockers and target-organ protection beyond blood pressure control
Neutel et al. P-437: Effects of fixed, low-dose combination amlodipine/benazepril therapy vs component monotherapy on systolic blood pressure: results of the select (systolic evaluation of lotrel efficacy and comparative therapies) trial

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180826